BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Semaglutide (Ozempic) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Semaglutide (Ozempic)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06954090-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT06954090)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Type 2 Diabetes.\nStudy: Urin
 ary Proteomics to Guide Early Intervention to Prevent Complications in Typ
 e 2 Diabetes - a Feasibility Study\nEstimated primary completion: 30 Novem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide
 -ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06954090
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570810-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Semaglutide (Ozempic): Phase na readout est. (NCT07570810)
DESCRIPTION:Semaglutide (Ozempic)\, phase na\, Type 2 Diabetes.\nStudy: Eff
 icacy\, Safety\, and Tolerability of CS0159 Combined With Semaglutide in M
 AFLD Patients With Obesity and T2DM\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutid
 e-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07570810
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067621-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT05067621)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2\, Type 2 Diabetes.\nStudy: Sema
 glutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes 
 and Metabolic Dysfunction-Associated Steatotic Liver Disease\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05067621
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059377-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07059377)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: Sema
 glutide for Smoking Cessation in Patients With Diabetes\nEstimated primary
  completion: December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07059377
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677995-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase na readout est. (NCT07677995)
DESCRIPTION:Semaglutide (Ozempic)\, phase na\, Type 2 Diabetes.\nStudy: Fre
 e Fatty Acid Effects In Type 2 Diabetes\nEstimated primary completion: Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semagluti
 de-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07677995
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06005012-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT06005012)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2\, Type 2 Diabetes.\nStudy: Sema
 glutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity a
 nd T2DM\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06005012
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449625-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT06449625)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Semaglutide in Auto-HS
 CT\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06449625
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06461377-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT06461377)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Type 2 Diabetes.\nStudy: The 
 Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy
 \nEstimated primary completion: 31 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06461377
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959784-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT06959784)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4.\nStudy: Assessing Incretin The
 rapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Stud
 y)\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06959784
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165158-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07165158)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Type 2 Diabetes.\nStudy: The 
 Effect of Semaglutide on Bone Health\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semagluti
 de-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07165158
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06691243-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT06691243)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Evaluation Of Semaglut
 ide in Adults With Cocaine Use Disorder With and Without HIV\nEstimated pr
 imary completion: January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06691243
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06894784-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT06894784)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: A Clinical Trial to Ev
 aluate The Effects of Semaglutide and Empagliflozin Combined to Automated 
 Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
 \nEstimated primary completion: January 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06894784
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509112-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07509112)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Semaglutide for Treatm
 ent of People With Methamphetamine Use Disorder: the SHIFT Study\nEstimate
 d primary completion: January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07509112
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07251556-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07251556)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4.\nStudy: GLP-1 Receptor Agonist
 s in Non-diabetic Patients With Psoriatic Arthritis\nEstimated primary com
 pletion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/semaglutide-ozempic#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07251556
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223983-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Semaglutide (Ozempic): Phase 1 readout est. (NCT07223983)
DESCRIPTION:Semaglutide (Ozempic)\, phase 1.\nStudy: Semaglutide (SEMA) for
  Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)\nE
 stimated primary completion: February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07223983
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314684-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07314684)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Type 2 Diabetes.\nStudy: GLP1
 -RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM\nEstimated
  primary completion: 8 March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07314684
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015893-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT06015893)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Semaglutide Therapy fo
 r Alcohol Reduction (STAR)\nEstimated primary completion: 31 March 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT060158
 93
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483801-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07483801)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4.\nStudy: DECODE - Haemodynamic 
 Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies\nEstima
 ted primary completion: April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07483801
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06184633-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT06184633)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4.\nStudy: DUTCH Weight Control i
 n Atrial Fibrillation Study\nEstimated primary completion: 10 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06184
 633
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05071898-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Semaglutide (Ozempic): Phase 1 readout est. (NCT05071898)
DESCRIPTION:Semaglutide (Ozempic)\, phase 1\, Type 2 Diabetes.\nStudy: Phar
 macogenetics of Response to GLP1R Agonists\nEstimated primary completion: 
 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semagl
 utide-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05071898
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05586802-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT05586802)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Sex Steroids Balance f
 or Metabolic and Reproductive Health in Klinefelter Syndrome\nEstimated pr
 imary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05586802
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548490-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT06548490)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: GLP-1R Agonist Treatme
 nt for Opioid Use Disorder\nEstimated primary completion: 30 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065484
 90
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05822609-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT05822609)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2\, Chronic Kidney Disease.\nStud
 y: Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes\nEs
 timated primary completion: June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05822609
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07317115-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Semaglutide (Ozempic): Phase na readout est. (NCT07317115)
DESCRIPTION:Semaglutide (Ozempic)\, phase na\, Type 2 Diabetes.\nStudy: Sid
 e-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and 
 Type 2 Diabetes\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07317115
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07040592-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07040592)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Off-Label Medications 
 for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutid
 e\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07040592
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07017270-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07017270)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Chronic Kidney Disease.\nStud
 y: Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Mainten
 ance Dialysis\nEstimated primary completion: July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07017270
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07030621-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07030621)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Efficacy of Semaglutid
 e in Improving Neurological Outcomes After Endovascular Thrombectomy for A
 cute Ischemic Stroke: A Randomized Double-Blind Controlled Trial\nEstimate
 d primary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07030621
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06042153-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT06042153)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Type 2 Diabetes.\nStudy: DIAL
 YSIS-TIR Study\nEstimated primary completion: September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06042153
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06639464-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT06639464)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Semaglutide for Helpin
 g Opioid Recovery\nEstimated primary completion: 1 September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06639464
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05819138-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT05819138)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Type 1 Diabetes Impact
 s of Semaglutide on Cardiovascular Outcomes\nEstimated primary completion:
  1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sema
 glutide-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05819138
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05938712-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT05938712)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: The Efficacy\, Mechani
 sm & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like P
 eptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipie
 nts\nEstimated primary completion: 1 October 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05938712
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908694-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT06908694)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4.\nStudy: Investigation of GLP1-
 Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation 
 Therapy\nEstimated primary completion: 31 October 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06908694
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03811561-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20271107
DTEND;VALUE=DATE:20271108
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT03811561)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: A Re
 search Study to Look at How Semaglutide Compared to Placebo Affects Diabet
 ic Eye Disease in People With Type 2 Diabetes\nEstimated primary completio
 n: 7 November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 emaglutide-ozempic#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03811561
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06387199-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Semaglutide (Ozempic): Phase 2/3 readout est. (NCT06387199)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2/3.\nStudy: Alleviating Carbohyd
 rate Counting for Patients With Type-1 Diabetes Using a Closed Loop System
  With Weekly Subcutaneous Semaglutide\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide
 -ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06387199
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874932-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Semaglutide (Ozempic): Phase na readout est. (NCT07874932)
DESCRIPTION:Semaglutide (Ozempic)\, phase na.\nStudy: Long-Term Effects of 
 Semaglutide on Body Composition and Performance in Running\nEstimated prim
 ary completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07874932
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874971-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Semaglutide (Ozempic): Phase na readout est. (NCT07874971)
DESCRIPTION:Semaglutide (Ozempic)\, phase na.\nStudy: Short Term Effects of
  Semaglutide on Body Composition and Performance\nEstimated primary comple
 tion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/semaglutide-ozempic#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07874971
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614412-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07614412)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: SHIELD-T1D: Shingrix a
 nd GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabete
 s.\nEstimated primary completion: 31 January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07614412
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788626-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT06788626)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Glucagon-like Peptide 
 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascul
 ar Treatment\nEstimated primary completion: February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06788626
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05819853-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT05819853)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Role of Semaglutide in
  Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome\nE
 stimated primary completion: 1 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05819853
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202247-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280409
DTEND;VALUE=DATE:20280410
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07202247)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Metabolic Intervention
 s (Time-Restricted Eating\, GLP1 Receptor Agonist\, and Heart Healthy Diet
 ) to Improve Cardiometabolic Health in Prostate Cancer Patients During And
 rogen Deprivation Therapy\, IMPACT-ADT Trial\nEstimated primary completion
 : 9 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semag
 lutide-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07202247
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06411210-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT06411210)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Obesity Complicating T
 ype 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment\nEstimated primary c
 ompletion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06411210
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07523633-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07523633)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Effect of Semaglutide 
 on Cannabis Use in Adults With Cannabis Use Disorder\nEstimated primary co
 mpletion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/semaglutide-ozempic#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07523633
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563699-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Semaglutide (Ozempic): Phase 1/2 readout est. (NCT07563699)
DESCRIPTION:Semaglutide (Ozempic)\, phase 1/2\, Type 2 Diabetes.\nStudy: Sa
 fety\, Tolerability and Efficacy of Semaglutide Depot in Subjects With Typ
 e-2 Diabetes Mellitus\nEstimated primary completion: May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07563699
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06986993-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT06986993)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4.\nStudy: Impact of Semaglutide 
 on Tobacco Use and Related Health Behaviors\nEstimated primary completion:
  30 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglu
 tide-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06986993
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325500-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07325500)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Incretin Microdosing f
 or Cardiometabolic Health in People With HIV\nEstimated primary completion
 : 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semagl
 utide-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07325500
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239570-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07239570)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Chronic Kidney Disease.\nStud
 y: A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients 
 With Chronic Kidney Disease\nEstimated primary completion: June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07239570
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613437-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280614
DTEND;VALUE=DATE:20280615
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07613437)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: GLP-1 Receptor Agonist
  in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial\nEstimate
 d primary completion: 14 June 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07613437
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07627191-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Semaglutide (Ozempic): Phase 1 readout est. (NCT07627191)
DESCRIPTION:Semaglutide (Ozempic)\, phase 1.\nStudy: GLP-1 RA Plus SOC Trea
 tment in First-line\, Metastatic Pancreatic\, Colorectal\, or Hepatocellul
 ar Cancer\nEstimated primary completion: 30 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07627191
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07065383-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Semaglutide (Ozempic): Phase na readout est. (NCT07065383)
DESCRIPTION:Semaglutide (Ozempic)\, phase na\, Type 2 Diabetes.\nStudy: Reb
 alancing the Fat Content of the Heart and Muscles\nEstimated primary compl
 etion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 semaglutide-ozempic#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07065383
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073053-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07073053)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Type 2 Diabetes.\nStudy: The 
 Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Disea
 ses and Their Potential Mechanisms\nEstimated primary completion: 31 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-oze
 mpic#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07073053
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05305794-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT05305794)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Effect of Weekly GLP1 
 Agonist Treatment in "Double Diabetes"\nEstimated primary completion: Augu
 st 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-
 ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05305794
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07617155-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07617155)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: GLP-1 Agonists for Prevention of Recurrent Hypertriglyc
 eridemic Acute Pancreatitis\nEstimated primary completion: September 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761
 7155
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706284-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT06706284)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Type 2 Diabetes.\nStudy: Glyc
 emic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Sp
 inal Cord Injury and Type 2 Diabetes\nEstimated primary completion: 1 Sept
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semagluti
 de-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06706284
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891156-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Semaglutide (Ozempic): Phase 2/3 readout est. (NCT07891156)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2/3.\nStudy: Lean Mass Changes Wi
 th Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.\nEst
 imated primary completion: 1 September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07891156
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511543-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07511543)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Glucagon-like Peptide-
 1 Receptor Agonists for Endovascular Stroke Thrombectomy\nEstimated primar
 y completion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07511543
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07428746-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07428746)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: Inve
 stigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Femal
 e Adults With Diabetes\nEstimated primary completion: November 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07428746
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581145-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07581145)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: Effe
 ct of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients\nE
 stimated primary completion: December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07581145
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227948-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20290128
DTEND;VALUE=DATE:20290129
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07227948)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Repurposing Semaglutid
 e for the Treatment of Cocaine Use Disorder\nEstimated primary completion:
  28 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sem
 aglutide-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07227948
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07879612-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20290130
DTEND;VALUE=DATE:20290131
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07879612)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Semaglutide for the Tr
 eatment of Cannabis Use Disorder\nEstimated primary completion: 30 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-oz
 empic#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07879612
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218354-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07218354)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Cessation or Reduction
  of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alc
 ohol Use Disorder (CRAVE)\nEstimated primary completion: 31 March 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0721835
 4
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547878-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07547878)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Type 2 Diabetes.\nStudy: Rapi
 d and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RA
 PID-CKD)\nEstimated primary completion: 31 March 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07547878
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389941-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07389941)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4.\nStudy: Semaglutide PrIor to C
 athEeter Ablation in Patients With Atrial Fibrillation\nEstimated primary 
 completion: April 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/semaglutide-ozempic#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07389941
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485062-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07485062)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Type 2 Diabetes.\nStudy: Exer
 cise and Diabetes Interventions to Improve Brain Health in Older Adults Wi
 th Type 2 Diabetes\nEstimated primary completion: 1 May 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07485062
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651319-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Semaglutide (Ozempic): Phase 1/2 readout est. (NCT07651319)
DESCRIPTION:Semaglutide (Ozempic)\, phase 1/2.\nStudy: Interleukine-2 (IL-2
 ) Plus Semaglutide in Alzheimer's Disease\nEstimated primary completion: J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide
 -ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07651319
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430332-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07430332)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: GLP-1 RA for Stage 1 T
 ype 1 Diabetes\nEstimated primary completion: 1 June 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07430332
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082063-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT06082063)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Multifactorial Interve
 ntion to Reduce Cardiovascular Disease in Type 1 Diabetes\nEstimated prima
 ry completion: 1 July 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06082063
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900438-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20291220
DTEND;VALUE=DATE:20291221
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07900438)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4\, Type 2 Diabetes.\nStudy: A Re
 search Study Looking at Kidney and Heart Health in Adults With Type 2 Diab
 etes and Chronic Kidney Disease Treated With Semaglutide in China\nEstimat
 ed primary completion: 20 December 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07900438
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06058585-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT06058585)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Chronic Kidney Disease.\nStud
 y: The Chronic Kidney Disease Adaptive Platform Trial Investigating Variou
 s Agents for Therapeutic Effect\nEstimated primary completion: 31 December
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-oz
 empic#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06058585
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204249-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20300215
DTEND;VALUE=DATE:20300216
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT07204249)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2.\nStudy: Glutide for Ending Met
 hamphetamine\nEstimated primary completion: 15 February 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07204249
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05569772-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT05569772)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Semaglutide for the Tr
 eatment of Glucose Intolerance in Women With Prior Gestational Diabetes\nE
 stimated primary completion: March 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05569772
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361874-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Semaglutide (Ozempic): Phase 4 readout est. (NCT07361874)
DESCRIPTION:Semaglutide (Ozempic)\, phase 4.\nStudy: IMPACT-MACS: Adrenalec
 tomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Sec
 retion\nEstimated primary completion: 31 May 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07361874
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586150-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Semaglutide (Ozempic): Phase na readout est. (NCT07586150)
DESCRIPTION:Semaglutide (Ozempic)\, phase na.\nStudy: Personalized Pharmaco
 -Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)\nEstimate
 d primary completion: July 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07586150
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770282-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07770282)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Efficacy and Safety of
  Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Sc
 hizophrenia With Metabolic Syndrome\nEstimated primary completion: 30 July
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-oz
 empic#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07770282
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772960-114@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Semaglutide (Ozempic): Phase 1 readout est. (NCT07772960)
DESCRIPTION:Semaglutide (Ozempic)\, phase 1.\nStudy: Semaglutide Dose Effec
 ts on Metabolic and Stress Hormone\, Craving and Alcohol Use Outcomes\nEst
 imated primary completion: 31 October 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07772960
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
